Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Still Needled By Icahn, Forest Nominates Three To Board

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.
Advertisement

Related Content

Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly
Deals Of The Week: Stiefel/Welichem, Bayer/Covance, Ensemble/Genentech
Forest Holds Off Icahn, But Battle Likely Looms
Forest Holds Off Icahn, But Battle Likely Looms
Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry
Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry
HHS Office of Inspector General Drops Challenge To Forest CEO Solomon
Icahn Is Forest’s Latest Wolf At The Door
Icahn Is Forest’s Latest Wolf At The Door
How Broadly Will OIG Enforce Its Exclusion Powers? Possible Action Against Forest CEO Offers A Lesson

Topics

Advertisement
UsernamePublicRestriction

Register

PS072619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel